Physician profile
Stacy Silvers
NPI 1467629337
$26,206.15
in general payments reported to CMS, 2019-2025
26 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $30.80 · 2021: $1,432 · 2022: $2,694 · 2023: $773 · 2024: $9,170 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $3,212 · Consulting Fee: $2,125 · Travel and Lodging: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,920.00 |
| Food and Beverage | $3,211.91 |
| Consulting Fee | $2,125.00 |
| Travel and Lodging | $1,520.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17,016.73 | 2022-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $2,267.22 | 2025 | Neffy |
| Optinose US, INC. | $1,624.12 | 2019-2025 | |
| Alk-Abello, INC | $1,298.42 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals Lp | $973.14 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $610.54 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $572.16 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $502.38 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $441.52 | 2019-2025 | Dupixent |
| Genzyme Corporation | $210.04 | 2020-2025 | |
| Kaleo, INC. | $190.27 | 2019-2023 | Auvi-Q |
| Inspire Medical Systems, INC. | $94.17 | 2025 | Inspire |
| Phadia US INC. | $72.63 | 2022-2024 | Immunocap |
| Aerin Medical INC. | $39.43 | 2022 | |
| Acclarent, INC | $38.62 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.79 | 2023 | Rinvoq |
| Pfizer INC. | $29.51 | 2022 | |
| Neurent Medical Limited | $26.15 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Aimmune Therapeutics, INC. | $25.93 | 2022 | |
| Pharming Healthcare, INC. | $25.53 | 2021 | |
| Grifols USA, LLC | $23.20 | 2025 | Xembify |
| Biocryst US Sales Co., LLC | $22.70 | 2023 | Orladeyo |
| Covis Pharma Gmbh | $21.46 | 2022 | |
| Leo Pharma INC. | $20.38 | 2022 | |
| Hikma Pharmaceuticals USA | $16.04 | 2023 | Ryaltris |
| Cycle Pharmaceuticals INC | $14.07 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Silvers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.